Millennium: Genes Are Not Enough
To push forward their gene-based discovery programs, drug firms need qualified targets, not simply genetic information. Millennium is trying to provide these targets—and its signing higher-value deals as a result.
You may also be interested in...
Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.
An explicit ban on patent linkage would ensure that competition to originator drugs is not delayed, according to off-patent industry group Medicines for Europe.
Members of the European Parliament have ignored pleas from the EPP political group and the German Federal Council to drop a proposal allowing third parties to oppose the granting of a supplementary protection certificate.